Testicular Mesothelioma - Diagnosis, Treatment, and Prognosis in 2026
Testicular mesothelioma is the rarest form of mesothelioma, accounting for less than 1 percent of all cases. It arises from the tunica vaginalis testis — the mesothelial lining that surrounds and protects the testicle, a remnant of the peritoneal lining that descends with the testis during fetal development.
Because so few cases exist, most of what is known about this disease comes from case reports, small case series, and registry analyses rather than clinical trials designed specifically for this population. That evidence base has grown meaningfully in recent years, and the 2025 Memorial Sloan Kettering series — the largest single-institution report to date — has provided new data on outcomes achievable with aggressive multidisciplinary treatment.
The rarity of testicular mesothelioma has a practical implication: most oncologists will never see a case in their career. Patients diagnosed with this disease need to reach centers with mesothelioma expertise. Treatment extrapolated from broader mesothelioma literature at a high-volume specialist program consistently outperforms treatment provided at centers that encounter this disease for the first time.
Learn about all forms of mesothelioma.
Symptoms and Initial Presentation
The most common presenting symptom of testicular mesothelioma is painless scrotal swelling, often associated with a hydrocele — an accumulation of fluid within the tunica vaginalis. The swelling is frequently present for months or even years before diagnosis, as it can be mistaken for a benign hydrocele or epididymal cyst.
Other presentations include a palpable scrotal mass, scrotal discomfort, or — less commonly — symptoms related to inguinal lymph node involvement. Because testicular mesothelioma is rare and the initial presentation mimics benign scrotal conditions, diagnosis is often delayed. In some cases the correct diagnosis is not made until after orchiectomy, when the surgical pathology report identifies the mesothelioma.
The median age at diagnosis is approximately 55 to 60 years, though cases have been reported across a wide age range. A hydrocele in a middle-aged man with a history of asbestos exposure should prompt imaging and pathological evaluation before assuming a benign etiology.
Diagnosis
Imaging. Scrotal ultrasound is the initial imaging modality of choice. It can identify the hydrocele, characterize any solid components, and guide decision-making about biopsy or surgical exploration. CT of the chest, abdomen, and pelvis is essential for staging and identifying lymph node involvement or distant metastases. PET-CT may provide additional information about disease extent.
Pathology. Because orchiectomy is both diagnostic and therapeutic for localized testicular mesothelioma, the pathological diagnosis is typically established on the surgical specimen rather than a preoperative biopsy. The tunica vaginalis is the site of origin, and the tumor may be papillary, solid, or mixed in architecture.
Immunohistochemistry. As with all mesothelioma, IHC is essential for confirming the diagnosis. The standard markers apply: calretinin, WT-1, CK5/6, and D2-40 are positive in epithelioid mesothelioma; markers such as CEA, MOC-31, and BerEP4 are negative. Distinguishing testicular mesothelioma from metastatic carcinoma involving the testis, or from adenomatoid tumor of the epididymis, requires careful IHC characterization.
Cell type. Testicular mesothelioma is most commonly epithelioid, though biphasic cases are reported. Pure sarcomatoid testicular mesothelioma is exceptionally rare.
Treatment
Treatment for testicular mesothelioma follows principles derived from the broader mesothelioma literature, adapted to the anatomical location and pattern of spread characteristic of this subtype.
Surgery. Radical inguinal orchiectomy is the standard first-line surgical treatment. This approach removes the testicle along with the tunica vaginalis through an inguinal incision, which avoids the scrotal approach that could seed the inguinal lymphatics with tumor cells.
Beyond orchiectomy, there is increasing evidence that more aggressive surgical approaches — particularly hemiscrototomy and retroperitoneal lymph node dissection (RPLND) — improve outcomes at specialized centers. The 2025 MSK series demonstrated that an aggressive multidisciplinary protocol combining radical inguinal orchiectomy with selective additional procedures and systemic therapy produced a median overall survival of approximately 4.5 years. This is roughly double the historical two-year benchmark that had been the standard reference point for testicular mesothelioma outcomes.
RPLND has been described as a potentially curative intervention for patients with isolated retroperitoneal lymph node recurrence. While the data are limited to case reports and small series, the procedure is consistent with established oncological principles for managing lymph node spread from urogenital tumors, and it is appropriate to discuss with the surgical team at a mesothelioma-specialized center.
Chemotherapy. Chemotherapy for testicular mesothelioma is extrapolated from pleural mesothelioma protocols. Platinum-based regimens combined with pemetrexed are the standard approach for patients with metastatic or recurrent disease. Response rates and survival data for testicular mesothelioma specifically are limited to small series and case reports; the available data suggest behavior broadly consistent with other mesothelioma subtypes of similar histology.
Immunotherapy. Checkpoint inhibitor immunotherapy — particularly the combination of nivolumab and ipilimumab, which received FDA approval for pleural mesothelioma in 2020 — is being applied to testicular mesothelioma based on the principle that mesothelioma of any anatomical origin shares fundamental biology. Case reports have documented responses to nivolumab plus ipilimumab in biphasic testicular mesothelioma. Clinical trial enrollment is appropriate when available.
Radiation. Radiation has a limited evidence base in testicular mesothelioma but may be considered for local disease control in specific clinical situations, consistent with its role in broader mesothelioma management.
Prognosis
Testicular mesothelioma historically carried a better prognosis than pleural mesothelioma, in part because its early presentation with scrotal symptoms often led to surgical resection before extensive spread. Population-based SEER analyses had suggested a median survival in the range of 24 to 30 months.
The 2025 MSK series updated this picture substantially. With aggressive multidisciplinary management at a specialized mesothelioma center, median overall survival reached approximately 4.5 years — a figure that suggests meaningful long-term disease control is achievable for a meaningful proportion of patients.
The factors most consistently associated with better prognosis are epithelioid histology, early-stage disease at presentation, complete surgical resection, and treatment at a high-volume mesothelioma center. Biphasic and sarcomatoid histologies carry worse prognosis, consistent with the pattern seen in other mesothelioma anatomical sites.
Recurrence after initial treatment is common. Retroperitoneal and peritoneal recurrences are the most typical patterns. Management of recurrent disease follows the same general principles as first-line treatment: multidisciplinary assessment, consideration of repeat surgical resection where feasible, and systemic therapy.
The Asbestos Connection
Testicular mesothelioma is caused by asbestos exposure. The asbestos fibers that reach the tunica vaginalis are thought to travel through the body after inhalation or ingestion, ultimately reaching the peritoneal cavity and descending into the tunica vaginalis — the same anatomical pathway by which the testicle itself descended during fetal development.
A 2020 case-control study by Marinaccio et al. documented a strong association between occupational asbestos exposure and testicular mesothelioma, providing epidemiological confirmation of the causal relationship that was already established for mesothelioma at other anatomical sites. The latency between first asbestos exposure and diagnosis spans 20 to 50 years.
The occupations most commonly associated with asbestos exposure — insulation workers, pipefitters, boilermakers, shipyard workers, construction trades, mechanics, and military personnel — are the same occupations from which testicular mesothelioma patients are disproportionately drawn.
Learn more about asbestos exposure by occupation. | Learn more about military asbestos exposure.
Financial Costs of Treatment
Testicular mesothelioma treatment is expensive. Surgery, particularly when it involves orchiectomy plus additional procedures, generates hospital costs. Systemic therapy with pemetrexed-based chemotherapy or checkpoint immunotherapy carries medication costs that can exceed $150,000 annually for immunotherapy. Imaging, oncology visits, and supportive care add to the total.
A 2019 study by Borrelli et al. examined hospitalization costs for patients with testicular mesothelioma in the United States and found significant variation by region and age group, with costs that create substantial financial burden even for patients with insurance. The gap between what insurance covers and what the best available care requires is one of the direct consequences of a disease caused by someone else's decisions.
That gap is precisely what legal compensation is designed to close.
Legal and Financial Options
If you have testicular mesothelioma and a history of asbestos exposure — or even if you don't recall a specific exposure but have received this diagnosis — there is a high likelihood that your cancer was caused by asbestos products manufactured and sold by companies that knew what those products would do.
Asbestos Trust Fund Claims. More than 60 asbestos compensation trusts hold combined assets in excess of $30 billion. Claims are paper-based, require no courtroom appearance, and are typically prioritized for mesothelioma patients. Initial payments often arrive within 30 days of filing. Most patients qualify for claims against multiple trusts. Our firm maintains a proprietary database of over 200,000 verified asbestos exposure sites, cross-referenced with products and manufacturers, which allows us to identify relevant trusts even when patients cannot recall specific product names.
Learn more about asbestos trust fund claims.
Mesothelioma Lawsuits. When the company responsible for your exposure is still operating, a personal injury lawsuit may be appropriate and can result in compensation substantially exceeding trust fund payments. Most mesothelioma cases settle before trial. For families who have lost someone to testicular mesothelioma, wrongful death claims follow the same framework.
Learn more about mesothelioma lawsuits.
VA Benefits for Veterans. Veterans exposed to asbestos during military service may qualify for monthly tax-free VA disability compensation and full VA healthcare coverage. Disability ratings for mesothelioma are typically 100%. VA benefits can be pursued alongside trust fund claims and personal injury lawsuits without affecting eligibility for any of them.
Learn more about VA benefits for mesothelioma.
Social Security Disability (SSDI). Mesothelioma qualifies for the Social Security Administration's Compassionate Allowances program, which fast-tracks disability benefit approval to weeks rather than months. SSDI approval also accelerates Medicare eligibility.
Learn more about SSDI for mesothelioma.
About Our Firm
The Law Offices of Justinian C. Lane, Esq. – PLLC has recovered more than $400 million for asbestos victims since 2014. Our founding attorney lost multiple family members to asbestos-related cancers and is himself a cancer survivor. That experience shapes how this firm operates: we treat every client as if they were family, because we understand what this diagnosis means in a way that extends beyond the legal file.
We represent mesothelioma patients and their families nationwide, with offices in Texas, Arizona, California, and Washington. We work on a contingency fee basis with no upfront costs and no fees unless we recover compensation for you.
Take the Next Step
If you or a family member has been diagnosed with testicular mesothelioma, we can help you understand your options, identify the responsible companies, file trust fund claims and lawsuits simultaneously, pursue VA benefits and SSDI if applicable, and coordinate the legal process to create the least possible disruption to your treatment.
Call 833-4-ASBESTOS (833-427-2378) or schedule your free consultation online.
References
Agrawal P, et al. (2025). Malignant mesothelioma of the tunica vaginalis testis: A single-institution case series. Annals of Surgical Oncology. Memorial Sloan Kettering Cancer Center.
Stella S, et al. (2024). Malignant mesothelioma of the tunica vaginalis: A comprehensive review of the literature (1982-2024). Cancers, 16. https://doi.org/10.3390/cancers16
Marinaccio A, et al. (2020). Malignant mesothelioma of the tunica vaginalis testis: A case-control study on asbestos exposure. Scandinavian Journal of Work, Environment & Health, 46(6), 609-614. https://doi.org/10.5271/sjweh.3907
Janes WCI, et al. (2023). Retroperitoneal lymph node dissection for recurrent testicular mesothelioma: A case report. Case Reports in Oncology, 16, 1207-1213. https://doi.org/10.1159/000534375
Mishra K, et al. (2023). Partial response to nivolumab and ipilimumab in metastatic biphasic mesothelioma of the tunica vaginalis. Clinical Case Reports, 11(3), e7096. https://doi.org/10.1002/ccr3.7096
Grogg JB, et al. (2021). Testicular mesothelioma: A pooled case-series analysis. Journal of Cancer Research and Clinical Oncology, 147, 3037-3044. https://doi.org/10.1007/s00432-021-03609-9
Borrelli E, et al. (2019). Hospitalization costs for patients with testicular mesothelioma in the United States. Rare Tumors, 11. https://doi.org/10.1177/2036361319886567
Nazemi A, et al. (2019). Testicular mesothelioma: An analysis of epidemiology, treatment, and outcomes from the Surveillance, Epidemiology, and End Results database. Urology, 126, 140-146. https://doi.org/10.1016/j.urology.2018.12.025
Carbone M, Ly BH, Dodson RF, et al. (2012). Malignant mesothelioma: Facts, myths, and hypotheses. Journal of Cellular Physiology, 227(1), 44-58. https://doi.org/10.1002/jcp.22724